Viva Biotech completes HKD 18.50 million share buy-back, taking May repurchases to 12.22 million shares

Bulletin Express05-20

Viva Biotech Holdings disclosed that it repurchased an additional 0.60 million ordinary shares on 20 May 2026 at prices ranging from HKD 1.43 to HKD 1.45 per share. The transaction cost HKD 0.87 million, lifting the total shares bought back between 8–20 May to 12.22 million.

Including the latest purchase, the aggregate consideration for the May programme stands at approximately HKD 18.50 million, translating into a volume-weighted average repurchase price of about HKD 1.51 per share. The cumulative 12.22 million shares represent 0.57% of Viva Biotech’s issued share capital of 2.13 billion shares as at 19 May 2026.

All repurchased shares—spanning nine market sessions—remain outstanding pending cancellation. Consequently, the Company’s issued share count was unchanged at 2.13 billion shares as of the close on 20 May 2026.

The repurchases were executed under the general mandate approved by shareholders on 12 June 2025, which authorises the Company to buy back up to 212.84 million shares. Following the latest transactions, 200.63 million shares, or 94.3% of the mandate, remain available.

In line with Hong Kong Stock Exchange rules, Viva Biotech is subject to a moratorium on issuing new shares or disposing of treasury shares until 19 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1162905182?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 18:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162905182","market":"hk","top_or_hot":-1,"title":"Viva Biotech completes HKD 18.50 million share buy-back, taking May repurchases to 12.22 million shares","media":"Bulletin Express","content":"<p>Viva Biotech Holdings disclosed that it repurchased an additional 0.60 million ordinary shares on 20 May 2026 at prices ranging from HKD 1.43 to HKD 1.45 per share. The transaction cost HKD 0.87 million, lifting the total shares bought back between 8–20 May to 12.22 million.</p>\n<p>Including the latest purchase, the aggregate consideration for the May programme stands at approximately HKD 18.50 million, translating into a volume-weighted average repurchase price of about HKD 1.51 per share. The cumulative 12.22 million shares represent 0.57% of Viva Biotech’s issued share capital of 2.13 billion shares as at 19 May 2026.</p>\n<p>All repurchased shares—spanning nine market sessions—remain outstanding pending cancellation. Consequently, the Company’s issued share count was unchanged at 2.13 billion shares as of the close on 20 May 2026.</p>\n<p>The repurchases were executed under the general mandate approved by shareholders on 12 June 2025, which authorises the Company to buy back up to 212.84 million shares. Following the latest transactions, 200.63 million shares, or 94.3% of the mandate, remain available.</p>\n<p>In line with Hong Kong Stock Exchange rules, Viva Biotech is subject to a moratorium on issuing new shares or disposing of treasury shares until 19 June 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viva Biotech completes HKD 18.50 million share buy-back, taking May repurchases to 12.22 million shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViva Biotech completes HKD 18.50 million share buy-back, taking May repurchases to 12.22 million shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-20 18:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Viva Biotech Holdings disclosed that it repurchased an additional 0.60 million ordinary shares on 20 May 2026 at prices ranging from HKD 1.43 to HKD 1.45 per share. The transaction cost HKD 0.87 million, lifting the total shares bought back between 8–20 May to 12.22 million.</p>\n<p>Including the latest purchase, the aggregate consideration for the May programme stands at approximately HKD 18.50 million, translating into a volume-weighted average repurchase price of about HKD 1.51 per share. The cumulative 12.22 million shares represent 0.57% of Viva Biotech’s issued share capital of 2.13 billion shares as at 19 May 2026.</p>\n<p>All repurchased shares—spanning nine market sessions—remain outstanding pending cancellation. Consequently, the Company’s issued share count was unchanged at 2.13 billion shares as of the close on 20 May 2026.</p>\n<p>The repurchases were executed under the general mandate approved by shareholders on 12 June 2025, which authorises the Company to buy back up to 212.84 million shares. Following the latest transactions, 200.63 million shares, or 94.3% of the mandate, remain available.</p>\n<p>In line with Hong Kong Stock Exchange rules, Viva Biotech is subject to a moratorium on issuing new shares or disposing of treasury shares until 19 June 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01873","symbol_name":"维亚生物","start_time":0,"source_url":"","article_id":"1162905182","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162905182","pubTimestamp":1779271377,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Viva Biotech Holdings disclosed that it repurchased an additional 0.60 million ordinary shares on 20 May 2026 at prices ranging from HKD 1.43 to HKD 1.45 per share. The transaction cost HKD 0.87...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01873":"维亚生物"},"translate_title":"维亚生物完成1850万港元股份回购5月回购达1222万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01873":1},"content_text":"Viva Biotech Holdings disclosed that it repurchased an additional 0.60 million ordinary shares on 20 May 2026 at prices ranging from HKD 1.43 to HKD 1.45 per share. The transaction cost HKD 0.87 million, lifting the total shares bought back between 8–20 May to 12.22 million.\nIncluding the latest purchase, the aggregate consideration for the May programme stands at approximately HKD 18.50 million, translating into a volume-weighted average repurchase price of about HKD 1.51 per share. The cumulative 12.22 million shares represent 0.57% of Viva Biotech’s issued share capital of 2.13 billion shares as at 19 May 2026.\nAll repurchased shares—spanning nine market sessions—remain outstanding pending cancellation. Consequently, the Company’s issued share count was unchanged at 2.13 billion shares as of the close on 20 May 2026.\nThe repurchases were executed under the general mandate approved by shareholders on 12 June 2025, which authorises the Company to buy back up to 212.84 million shares. Following the latest transactions, 200.63 million shares, or 94.3% of the mandate, remain available.\nIn line with Hong Kong Stock Exchange rules, Viva Biotech is subject to a moratorium on issuing new shares or disposing of treasury shares until 19 June 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1162905182","isCrawlerRequest":true}